New drug cocktail aims to stop kidney cancer comeback
Disease control
Recruiting now
This Phase 3 trial tests whether giving a combination of axitinib (a targeted therapy) and toripalimab (an immunotherapy) before surgery can help prevent kidney cancer from returning in high-risk patients. About 298 participants will either receive the drug combo followed by surg…
Phase: PHASE3 • Sponsor: ZHOU FANGJIAN • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC